1. Home
  2. News

News

Anticancer Fund and De Tijd expose shady cancer treatments in the media

Private cancer clinics under fire: Anticancer Fund and De Tijd expose shady treatments

We have uncovered alarming practices in private cancer clinics, where cancer patients are being charged tens of thousands of euros for unproven cancer treatments. We raised concerns about these dangerous practices to investigator journalists, to help protect cancer patients and and fight misinformation.

National Lottery players support My Cancer Navigator

National Lottery players support My Cancer Navigator, helping cancer patients get personalised information

The Anticancer Fund now receives support from the National Lottery for My Cancer Navigator, our free information service. This partnership will allow us to help more cancer patients.

This survey highlights the impact of My Cancer Navigator

Survey: My Cancer Navigator boosts patient confidence and knowledge

Happy to share the key findings from a survey we have done in partnership with KU Leuven and Optigage, highlighting the powerful impact of My Cancer Navigator, our personalized service designed to support cancer patients.

This is the homepage of the new website of My Cancer Navigator

My Cancer Navigator achieves crowdfunding goal and launches website

Discover how My Cancer Navigator, a free service offered by the Anticancer Fund, reached its crowdfunding goal and launched a new website to support cancer patients, families, and healthcare professionals with expert guidance and information.

Rare cancers call for projects - ATTRACT consortium

International call for research proposals on rare cancer drug development

The Anticancer Fund and five other charities collaborate to support innovative research and this way, bring more treatment options to patients with rare cancers. This is the second call for projects by the ATTRACT consortium.

A publication by scientists of the Anticancer Fund

High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial)

Julie De Smedt, Sofie Van Kelst, Laudine Janssen, Vivien Marasigan, Veerle Boecxstaens, Kris Bogaerts, Ann Belmans, Dirk Vanderschueren, Katleen Vandenberghe, Oliver Bechter, Claudia Aura, Diether Lambrechts, Tinne Strobbe, Gabriella Emri, Arjen Nikkels and Marjan Garmyn